Oral Biologics, Skin Grafts, Autologous Cell Transplants

Imagine Pharma is at the forefront of biotechnology, focusing on the development of its novel polypeptide, IMG-1, across three primary platforms: Oral Delivery, Therapeutics, and Regenerative Medicine. The Oral Delivery platform aims to revolutionize the administration of biologic drugs by allowing them to be taken orally rather than through injections, which could significantly enhance patient compliance and comfort. The Therapeutics platform is dedicated to creating innovative treatments that address various disease states, particularly where existing therapies are inadequate or non-existent. This includes a commitment to developing first-in-class therapies that can disrupt current treatment paradigms and improve patient outcomes.

In addition to these platforms, Imagine Pharma's Regenerative Medicine efforts are noteworthy for their ability to safely regenerate and propagate critical human cell types, such as insulin-producing islet cells. This capability is particularly significant for conditions like Type 1 diabetes, where the company is working on autologous islet transplantation to restore insulin production in patients. By leveraging its proprietary culture methods and the IMG-1 polypeptide, Imagine Pharma aims to scale the production of these cells, potentially addressing the high demand for islet transplants and improving the quality of life for patients suffering from chronic conditions. Through its innovative approaches, Imagine Pharma is committed to transforming patient care and outcomes in the field of biotechnology.

United States

Imagine Pharma is a biotechnology company focused on three distinctive platforms: oral delivery, regenerative and therapeutics. Each platform has first-in-class programs that address multiple disease states in large underserved markets.

Imagine Pharma

Company Details